[go: up one dir, main page]

WO2011029415A1 - Complexes cyclobutane-1,1-dicarboxylato de platine avec des dérivés de n6-benzyladénine, leur procédé de préparation et leur application en tant que médicaments dans un traitement antitumoral - Google Patents

Complexes cyclobutane-1,1-dicarboxylato de platine avec des dérivés de n6-benzyladénine, leur procédé de préparation et leur application en tant que médicaments dans un traitement antitumoral Download PDF

Info

Publication number
WO2011029415A1
WO2011029415A1 PCT/CZ2010/000098 CZ2010000098W WO2011029415A1 WO 2011029415 A1 WO2011029415 A1 WO 2011029415A1 CZ 2010000098 W CZ2010000098 W CZ 2010000098W WO 2011029415 A1 WO2011029415 A1 WO 2011029415A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
cycloalkyl
aryl
cycloheteroalkenyl
cycloheteroalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CZ2010/000098
Other languages
English (en)
Inventor
Zdeněk TRÁVNÍČEK
Igor Popa
Lukáš DVOŘÁK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palacky University Olomouc
Original Assignee
Palacky University Olomouc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palacky University Olomouc filed Critical Palacky University Olomouc
Priority to EP10776530A priority Critical patent/EP2475673A1/fr
Publication of WO2011029415A1 publication Critical patent/WO2011029415A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention that belongs to the area of the platinum-based drugs against tumour diseases, relates to the platinum cyclobutane-1 , 1 -dicarboxylato complexes involving the N6-benzyladenine derivatives, and their use in the medical practice as drugs and pharmaceutical compositions, which contain these complexes as the active substance.
  • Cisplatin (a), c/ ' s-[PtCI 2 (NH 3 ) 2 ], c/ ' s-diamminedichlorido-platinum(ll) complex is one of the well-known platinum complexes used for the treatment of cancer (Rosenberg, B.; Camp, V.; Krigas, T. Nature 1965, 205, 689-699). It has been used in chemotherapy against tumours of testis, ovary, neck, head, or other types of tumour diseases (Weiss, R. B.; Christian, M. C. Drugs 1993, 46, 360-365). The chemotherapy itself is accompanied by negative side effects on the organism, such as nephrotoxicity or ototoxicity.
  • Carboplatin (b) is effective against almost the same human cancer cell lines as cisplatin (a) and it is also administered intravenously (Hambley, T. W.; Dalton Trans. 2001, 120, 2711-2718). Contrary to cisplatin the toxicity to organism is much lower, which leads to the significant decrease of the negative side effects ( Wilkinson, A. R.; Cox, P. J.; Jones, M.; Harrap, K. R. Biochimie 1978, 60, 851). Carboplatin (called JM- 8) was the first substance to be reported as in vivo cytotoxic active against testicular cancer, lung cancer (V79) and breast tumour (MTG-B) in 1985 (Peckham, M.
  • oxaliplatin [ 7R,2/R-diamminecyclohexane-N,N ' -]-(oxalato-0,0 ' )platinum(ll) complex, synthesized for the first time in 1978 (Kidani, Y.; Inagaki, K. J. Med. Chem., 1978, 21, 1315- 1318, EP2029615 - A proces for the preparation of an oxaliplatin, EP1979369 - Preparation of platinum(ll) complexes), whose molecular structure was determined in 1984 (Bruck, M.
  • N6-benzyladenine itself belongs to the group of natural plant growth regulators called cytokinins (Skoog, F.; Hamzi, H. Q.; Szweykowska, A. M.; Leopard, N. J.; Carraway, K. L; Fujii, T.; Helgeson, J. P.; Loeppky, R. N. Phytochem. 1967, 6, 1169-1192).
  • WO 0043394 Substituted nitrogen heterocyclic derivatives process of their preparation, the derivatives employed as medicaments, pharmaceutical composition and a compound pharmaceutical preparation in which these derivatives are comprised as well as use of these derivatives for preparing medicaments
  • WO 03040144 Heterocyclic compounds based on N6-substituted adenine, processes of their preparation, their use for preparing medicaments, cosmetic compositions and growth regulators and pharmaceutical preparations, cosmetic compositions and growth regulators containing such compounds
  • WO 0149688 Purine derivatives, process of their preparation and use
  • WO 2004058791 Substituting derivatives of N6-benzyladenosine, process of their preparation, their use in the
  • L 8 4,4-bis- (aminomethyl)tetrahydrofuran (Bitha, P.; Child, R. G.; Hlavka, J. J.; Lang, S.A.; Lin, Y - /.; Haltiwanger, R. C.; Pierpont, C. G. Inorg. Chim. Acta 1988, 151, 89-93),
  • L 9 1 ,3- dihydroxy-2,2-bis(aminomethyl)propane (Bitha, P.; Child, R. G.; Hlavka, J.J.; Lang, S.A.; Lin, Y.-i; Haltiwanger, R. C.; Pierpont, C.
  • L 12 bis(2-pyridyl)ketone (Ferreira, A.D. Q.; Bino, A.; Gibbon, D. Inorg. Chim. Acta 1997, 265, 155-161)
  • L 13 (3,6,9, 12- tetraoxatetradecane-1 , 14-diyl-2,2'-bipyridyl-3,3'-dicarboxylate (Yoo, J.; Sohn, Y.S.; Do, Y. J. Inorg. Biochem. 1999, 73, 187-193)
  • L 14 2,3-bis-(2-pyridyl)pyrazine (Ferreira, A.D.
  • Cyclobutane-1 , 1-dicarboxylato complexes of platinum in the oxidation state +II and their crystal-solvates including a structural motif I or having the general formula II expressed by the structural formula [Pt(cbdc)(L) 2 ] or the general formula III expressed by the structural formula [Pt(cbdc)(L)(L ' )], where the symbols L and L ' stand for N6-benzyladenine derivatives of the general formula IV bonded to the platinum atom of the basic motif V through any adenine nitrogen atom independently chosen from the N1 , N3, N6, N7 or N9 atoms, depending on the substitution rate of the molecules, where the substituent R1 , R2, R3 and R4 are independently chosen from the group of:
  • - alkenyl as employed herein by itself or as a part of another group represents a straight or branched hydrocarbon chain from up to 18, preferably from 2 to 8 carbon atoms, including at least one carbon-carbon double bond,
  • cyclic hydrocarbon chain from 3 to 12, preferably from 3 to 8 carbon atoms, which may be fused with 1 or 2 cycles which are independently selected from the group consisting of cycloalkyl, cycloheteroalkyl, cycloalkenyl, cycloheteroalkenyl, aryl a heteroaryl,
  • cykloalkyl where at least one carbon atom is exchanged for a heteroatom from the group consisting of nitrogen, oxygen, sulphur,
  • cycloheteroalkyl including at least one carbon-carbon, carbon-heteroatom, or heteroatom-heteroatom double bond
  • - functional group as employed herein by itself or as a part of another group represents amino, al- kylamino, dialkylamino, alkenylamino, cycloalkylamino, cycloheteroalkylamino, cyc- loalkenylamino, cycloheteroalkenylamino, arylamino, heteroarylamino, acylamino, hydroxy, alkylhydroxy, alkoxy, aryloxy, cyano, carboxy, alkylcarboxy, carboxyalkyl, aryl- carboxy, carboxyaryl, hydroxyamino, acyl, nitro, amido, nitroso, sulfonyl, sulfinyl, sulf- amido, thio, alkylthio, arylthio, merkapto, carbamoyl, - - substituted alkyl, substituted alkenyl, substituted alkynyl, substitute
  • alkyl alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, cycloalkenyl, cycloheteroalkenyl, aryl and heteroaryl substituted by the substituents from the group consisting of halogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, cycloalkenyl, cycloheteroalkenyl, aryl, heteroaryl and a functional group.
  • the next objective of the invention are crystal-solvates of the platinum(ll) cyclobu- tane-1 , 1 -dicarboxylato complex of the general formula [Pt(cbdc)(L) 2 ] xSolv or [Pt(cbdc) (L)(L ' )] xSolv, where (xj represents the number of the solvate molecules, preferably 1 to 6, and (Solv) represents a concrete molecule of the used solvent and/or some of the reaction components, usually chosen from the group consisting of water, primary alcohol, secondary alcohol, acetone, ⁇ /, ⁇ / ' -dimethylformamide (DMF), dimethyl sulfoxide (DMSO), chloroform, dichloromethane, acetonitrile or diethyl ether, either individually or in combinations of the mentioned solvate molecules.
  • DMF dimethyl sulfoxide
  • the invention also provides a pharmaceutical and pharmacological substance containing a therapeutically effective amount of the platinum(ll) cyclobutane-1 , 1 -di- carboxylato complexes or a pharmaceutical composition of the platinum(ll) cyclobutane-1 , 1 -dicarboxylato complexes with one or more acceptable carriers and additional substances for medicinal use as a drug for tumour diseases.
  • Fig. 1 represents the 13 C NMR spectrum of bis[2-chloro-6-(3,4-dichlorobenzyl)- amino-9-isopropylpurino]-cyclobutane-1 , 1 -dicarboxylato-platinum(ll) complex, [Pt(cbdc)(L 2 )2], given with the interpretation of the individual carbon atoms, which were detected by the 13 C, APT, 1 H- 13 C gs-HMQC and 1 H- 13 C gs-HMBC experiments
  • Fig. 2 represents the FT IR spectrum of the bis[2-chloro-6-(2-fluoro-5-bromobenzyl)- amino-9-isopropylpurino]-cyclobutane-1 ,1-dicarboxylato-platinum(ll) complex, [Pt(cbdc)(L ) 2 ], measured in the 400-4000 cm "1 range and given with the maxima characterizing the individual atom groups
  • Fig. 3 represents the FT IR spectrum of the bis[2-chloro-6-(2-fluoro-5-bromobenzyl)- amino-9-isopropylpurino]-cyclobutane-1 , 1 -dicarboxylato-platinum(ll) complex, [Pt(cbdc)(L 8 ) 2 ], measured in the 150-4000 cm -1 range and given with the maxima characterizing the Pt-N and Pt-0 vibrations
  • Fig. 4 represents the Raman spectrum of the bis[2-(3-hydroxypropylamino)-6- benzylamino-9-isopropylpurino]-cyclobutane-1 ,1-dicarboxylato-platinum(ll) complex, [Pt(cbdc)(L 1 ) 2 ], measured in the 400-4000 cm "1 range and given with the maxima characterizing the individual atom groups
  • Fig. 5 represents the molecular structure of the complex [2-chloro-6-(2- methoxybenzyl)amino-9- ' isopropylpurino]-(dimethylsulfoxid-S)-cyclobutane-1 ,1-dicarb- oxylato-platinum(ll) complex monohydrate, [Pt(cbdc)(DMSO)(L 7 )] H 2 0, determined by a single crystal X-ray analysis and with non-hydrogen atoms drawn as thermal ellipsoids at the 50% probability level. H-atoms are omitted for clarity.
  • the derivative L ' can be, from the chemical and structural point of view, towards L:
  • the invention also uses c/s-[PtCI 2 (DMSO) 2 ] and [Pt(cbdc)(DMSO) 2 ], where cbdc is dianion of the cyclobutane- ,1 -dicarboxylic acid, as the intermediates for the preparation of platinum cyclobutane-1 , 1 -dicarboxylato complexes of the general formula II or III, which can be prepared by the reaction of platinum chloride, PtCI 2 , with dimethyl sulfoxide (DMSO) leading, at raised temperature, to c/ ' s-[PtCI 2 (DMSO) 2 ] (Rochon, F. D.; Massarweh, G. Inorg. Chim.
  • Scheme 1 salt is added.
  • the reaction mixture is stirred in darkness at low temperature for several days.
  • the [Pt(cbdc)(DMSO) 2 ] complex is formed (Scheme 1 ).
  • Detail description of the preparation of this intermediate was reported in Bitha, P.; Morton, G. O.; Dunne, T. S.; Santos, E. F. D.; Lin, Y.; Boone, S. R.; Haltiwanger, R. C; Pierpoint, C. G. Inorg. Chem. 1990, 29, 645-652.
  • FT IR infrared spectroscopy
  • the invention employs [Pt(cbdc)(DMSO) 2 ] as a starting platinum compound.
  • This complex is not commercially available, but it can be prepared according to the synthetic procedure described in the literature (Bitha, P.; Morton, G. O.; Dunne, T. S.; Santos, E. F. D.; Lin, Y.; Boone, S. R.; Haltiwanger, R. C; Pierpoint, C. G. Inorg. Chem. 1990, 29, 645-652, Scheme 2).
  • the percentual content of the C, H, N elements given as: calculated value (found value in parenthesis) for CioHi 8 0 6 PtS 2 : C, 24.3 (23.9); H, 3.7 (3.9)%.
  • Raman (i/KBr/crrr 1 ): 261 (w, Pt-N), 479 (w, Pt-O), 890 (m, C-H), 1339 (vs, N- H), 1586 (s, C N), 2942 (s, C-H 2 ), 3064 (s, C-H).
  • Example 2 Synthesis of bis[2-chloro-6-(2-fluoro-5-bromobenzylamino)-9-isopropyl- purino]-(cyclobutan-1 ,1-dicarboxylato)-platinum(ll) complex, [Pt(cbdc)(Li) 2 ] 0.1 g (0.2 mmol) of [Pt(cbdc)(DMSO) 2 ] was dissolved in 15 mL of distilled water at laboratory temperature. The solution of 0.16 g (0.4 mmol) of 2-chloro-6-(2-fluoro-6- bromobenzyl)amino-9-isopropylpurine (L ⁇ in 20 mL of isopropanol was added.
  • reaction mixture was stirred for 2 days until the grey product formed. It was filtered off, washed with cold distilled water and dried in dissicator over silica gel (Scheme 4).
  • the obtained complex was characterized by elemental analysis, FT IR, Raman and 1 H, 3 C and 195 Pt NMR spectroscopy.
  • Example 3 Synthesis of bis[2-(3-hydroxypropylamino)-6-benzylamino-9-isopropylpu- rino]-(cyclobutan-1 ,1-dicarboxylato)-platinum(ll) complex, [Pt(cbdc)(L 8 ) 2 ] 0.1 g (0.2 mmol) of [Pt(cbdc)(DMSO) 2 ] was dissolved in 15 mL of distilled water at laboratory temperature. The solution of 0.136 g (0.4 mmol) of 2-(3- hydroxypropylamino)-6-benzylamino-9-isopropylpurine (L 8 ) in 20 mL of isopropanol was added.
  • reaction mixture was stirred for 2 days until the grey product formed. It was filtered off, washed with cold distilled water and dried in dissicator over silica gel (Scheme 5).
  • the obtained complex was characterized by elemental analysis, FT IR, Raman and 1 H, 13 C and 95 Pt NMR spectroscopy.
  • Example 4 Synthesis of dimethylsulfoxido-[2-chloro-6-(2-methoxybenzylamino)-9- isopropylpurino]-(cyclobutan-1 ,1-dicarboxylato)-platinum(ll) complex, [Pt(cbdc) (DMSO)(L 7 )] 0.1 g (0.2 mmol) of [Pt(cbdc)(DMSO) 2 ] was dissolved in 15 mL of distilled water at laboratory temperature. The solution of 0.08 g (0.2 mmol) of 2-chloro-6-(2- methoxybenzyl)amino-9-isopropylpurine (L?) in 20 ml_ of isopropanol was added. The reaction mixture was stirred for 2 days (Scheme 6). The obtained grey product was filtered off, washed with cold distilled water and dried in dissicator over silica gel.
  • the colourless crystals suitable for a single crystal X-ray analysis, formed in the filtrate in several days.
  • the molecular structure of [Pt(cbdc)(DMSO)(L 7 )] H 2 0 was determined by the mentioned method using Oxford Xcalibur diffractrometer equipped by CrysAlis CCD detector (Oxford Diffraction, 2002). Data collection and reduction were performed using CrysAlis software [CrysAlis CCD and CrysAlis RED, Version 1.171.33.52, Oxford Diffraction Ltd., Abingdon, England, 2009]. The same software was used for data correction for an absorption effect by the empirical absorption correction using spherical harmonics, implemented in SCALE3 ABSPACK scaling algorithm.
  • One of the parameters, used for the evaluation of in vitro cytotoxic activity, is metabolic activity of viable cells.
  • micro-titration testing employing a Calcein AM is widely used for the quantification of cell proliferation and cytotoxicity. This method is applied for the screening of drugs or for chemosensitivity testing. This test recognizes only living cells and the degree of Calcein AM reduction corresponds to the amount of living cells.
  • a screening of in vitro cytotoxicity was performed against the breast adenocarcinoma (MCF-7) and chronic myelogenous erythroleukemia (K562) human cancer cell lines.
  • the cells were maintained in plastic tissue culture flasks in the DMEM medium (5 g/L of glucose, 2 mM of glutamine, 100 U/mL of penicillin, 100 pg/mL of streptomycine, 10% fetal calf serum and sodium hydrogen carbonate) for cell cultures.
  • the cell suspensions (ca 1.25 x 10 5 cells mL ) were pipetted (80 ⁇ _) into 96-well microplates. They were incubated at 37 °C in the C0 2 atmosphere for 24 hrs.
  • the tested platinum(ll) complexes were dissolved in N,N -dimethylformamide, diluted to the 0.2-25.0 ⁇ concentration and added to the incubated cancer cell suspension. Then the mixtures were incubated for 72 hrs at 37 °C, 100% humidity and in the C0 2 atmosphere. The Calcein AM solution was added followed by the incubation lasting 1 hr.
  • the living cancer cell fluorescence (FD) was measured at 485/538 nm (excitation/emission) on the Labsystem FIA Fluoroscan Ascent device (Microsystems).
  • the IC 50 values represent the concentration of the tested complexes lethal for 50% of the cancer cells.
  • the method is based on the ability of metabolic-active cells to reduce (by mitochondrial dehydrogenases) the yellow salt 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) leading to the blue formazane dye formation. Because the reduction proceeds only in the living cells, the cytotoxicity of various compounds can be determined using this process.
  • the insoluble formazane is quantified after dissolving in dimethyl sulfoxide (DMSO) with ammonium on the spectrophotometer (ELISA reader).
  • DMSO dimethyl sulfoxide
  • ELISA reader spectrophotometer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des complexes cyclobutane-1,1-dicarboxylato de platine dans l'état d'oxydation +II et leurs cristallosolvates comprenant l'unité structurale I ou répondant à la formule générale II exprimée par la formule structurale [Pt(cbdc)(L)2] II ou à la formule générale III exprimée par la formule structurale [Pt(cbdc)(L)(L')] III, les symboles L et L' représentant des dérivés de N6-benzyladénine de formule générale IV liés à l'atome de platine de l'unité de base V par un atome d'azote d'adénine quelconque indépendamment choisi parmi les atomes N1, N3, N6, N7 ou N9, en fonction du taux de substitution des molécules IV, les substituants R1, R2 et R3 étant indépendamment choisis dans l'ensemble suivant : atome d'hydrogène, atome d'halogène, groupes alkyle, alkyle substitué, alcényle, alcényle substitué, alcynyle, alcynyle substitué, cycloalkyle, cycloalkyle substitué, cyclohétéroalkyle, cyclohétéroalkyle substitué, cycloalcényle, cycloalcényle substitué, cyclohétéroalcényle, cyclohétéroalcényle substitué, aryle, aryle substitué, hétéroaryle, hétéroaryle substitué, groupe fonctionnel et groupe N-R'R », dans lequel R' et R » symbolisent indépendamment un atome d'hydrogène, un groupe alkyle, alkyle substitué, alcényle, alcényle substitué, alcynyle, alcynyle substitué, cycloalkyle, cycloalkyle substitué, cyclohétéroalkyle, cyclohétéroalkyle substitué, cycloalcényle, cycloalcényle substitué, cyclohétéroalcényle, cyclohétéroalcényle substitué, aryle, aryle substitué, hétéroaryle, hétéroaryle substitué et un groupe fonctionnel.
PCT/CZ2010/000098 2009-09-10 2010-08-31 Complexes cyclobutane-1,1-dicarboxylato de platine avec des dérivés de n6-benzyladénine, leur procédé de préparation et leur application en tant que médicaments dans un traitement antitumoral Ceased WO2011029415A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10776530A EP2475673A1 (fr) 2009-09-10 2010-08-31 Complexes cyclobutane-1,1-dicarboxylato de platine avec des dérivés de n6-benzyladénine, leur procédé de préparation et leur application en tant que médicaments dans un traitement antitumoral

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20090597A CZ302618B6 (cs) 2009-09-10 2009-09-10 Cyklobutan-1,1-dikarboxylátokomplexy platiny s deriváty N6-benzyladeninu, zpusoby jejich prípravy a použití techto komplexu jako léciv v protinádorové terapii
CZPV2009-597 2009-09-10

Publications (1)

Publication Number Publication Date
WO2011029415A1 true WO2011029415A1 (fr) 2011-03-17

Family

ID=43430692

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2010/000098 Ceased WO2011029415A1 (fr) 2009-09-10 2010-08-31 Complexes cyclobutane-1,1-dicarboxylato de platine avec des dérivés de n6-benzyladénine, leur procédé de préparation et leur application en tant que médicaments dans un traitement antitumoral

Country Status (3)

Country Link
EP (1) EP2475673A1 (fr)
CZ (1) CZ302618B6 (fr)
WO (1) WO2011029415A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187191A1 (fr) * 2015-05-18 2016-11-24 Medoc Pharmaceutical Co., Ltd. Co-cristal pharmaceutique et son utilisation
US10421770B2 (en) 2015-06-19 2019-09-24 Syn-Nat Products Enterprise LLC Pharmaceutical composition of carboplatin based co-crystals and use thereof
US10428099B2 (en) 2015-06-25 2019-10-01 Syn-Nat Products Enterprise LLC Pharmaceutical co-crystal composition and use thereof
US10980768B2 (en) 2015-06-19 2021-04-20 Syn-Nat Products Enterprise LLC Composition containing carboplatin and use

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4273755A (en) 1979-08-16 1981-06-16 Mpd Technology Corporation Preparation of platinum complexes
WO2000043394A1 (fr) 1999-01-26 2000-07-27 Ústav Experimentální Botaniky Av Cr Derives heterocycliques d'azote substitue et leur utilisation pharmaceutique
WO2001049688A1 (fr) 2000-01-07 2001-07-12 Universitaire Instelling Antwerpen Derives de purine, procede de preparation et utilisation de ces derniers
WO2003040144A2 (fr) 2001-08-02 2003-05-15 Ustav Experimentalni Botaniky Akademie Ved Ceske Republiky Composes heterocycliques a base d'adenine n6-substituee, procedes de preparation de ceux-ci, procedes d'utilisation de ceux-ci dans la preparation de medicaments, de preparations cosmetiques et de regulateurs de croissance, des preparations pharmaceutiques, des preparations cosmetiques et des regulateur
WO2004058791A2 (fr) 2002-12-30 2004-07-15 Ustav Experimentalni Botaniky Akademie Ved Ceske Republiky Derives de substitution de n6-benzyle adenosine, methodes de preparation associees, leur utilisation pour realiser des medicaments, des preparations cosmetiques et des regulateurs de croissance ; preparations pharmaceutiques, cosmetiques et regulateurs de croissance contenant ces composes
WO2008081927A1 (fr) 2006-12-29 2008-07-10 Astellas Pharma Inc. Procédé de traitement d'un cancer utilisant un agent anti-cancer en combinaison
EP1942884A2 (fr) 2005-11-04 2008-07-16 Merck and Co., Inc. Methodes destinees a traiter des cancers avec du saha, du carboplatine et du paclitaxel et d'autres polytherapies
EP1979369A1 (fr) 2006-01-30 2008-10-15 Platco Technologies (Proprietary) Limited Preparation de complexes de platine (ii)
WO2008135793A1 (fr) 2007-05-04 2008-11-13 Pharma Mar S.A. Combinaison d'aplidine et de carboplatine dans des traitements anticancéreux
EP2029615A1 (fr) 2006-06-08 2009-03-04 Vuab Pharma A. S. Procédé de préparation d'un oxaliplatine
WO2009043320A2 (fr) 2007-10-05 2009-04-09 Univerzita Palackeho V Olomouci Dérivés de 6.(alkylbenzylamini)purine substitués s'utilisant comme antagonistes du récepteur de la cytokine et préparations contenant ces dérivés

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ706U1 (cs) * 1991-05-06 1993-09-22 Agmeco, Spol. S R.O. Zavěšená váha s ústředním snímáním síly prostřednictvím závěsného tělesa

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4273755A (en) 1979-08-16 1981-06-16 Mpd Technology Corporation Preparation of platinum complexes
WO2000043394A1 (fr) 1999-01-26 2000-07-27 Ústav Experimentální Botaniky Av Cr Derives heterocycliques d'azote substitue et leur utilisation pharmaceutique
WO2001049688A1 (fr) 2000-01-07 2001-07-12 Universitaire Instelling Antwerpen Derives de purine, procede de preparation et utilisation de ces derniers
WO2003040144A2 (fr) 2001-08-02 2003-05-15 Ustav Experimentalni Botaniky Akademie Ved Ceske Republiky Composes heterocycliques a base d'adenine n6-substituee, procedes de preparation de ceux-ci, procedes d'utilisation de ceux-ci dans la preparation de medicaments, de preparations cosmetiques et de regulateurs de croissance, des preparations pharmaceutiques, des preparations cosmetiques et des regulateur
WO2004058791A2 (fr) 2002-12-30 2004-07-15 Ustav Experimentalni Botaniky Akademie Ved Ceske Republiky Derives de substitution de n6-benzyle adenosine, methodes de preparation associees, leur utilisation pour realiser des medicaments, des preparations cosmetiques et des regulateurs de croissance ; preparations pharmaceutiques, cosmetiques et regulateurs de croissance contenant ces composes
EP1942884A2 (fr) 2005-11-04 2008-07-16 Merck and Co., Inc. Methodes destinees a traiter des cancers avec du saha, du carboplatine et du paclitaxel et d'autres polytherapies
EP1979369A1 (fr) 2006-01-30 2008-10-15 Platco Technologies (Proprietary) Limited Preparation de complexes de platine (ii)
EP2029615A1 (fr) 2006-06-08 2009-03-04 Vuab Pharma A. S. Procédé de préparation d'un oxaliplatine
WO2008081927A1 (fr) 2006-12-29 2008-07-10 Astellas Pharma Inc. Procédé de traitement d'un cancer utilisant un agent anti-cancer en combinaison
WO2008135793A1 (fr) 2007-05-04 2008-11-13 Pharma Mar S.A. Combinaison d'aplidine et de carboplatine dans des traitements anticancéreux
WO2009043320A2 (fr) 2007-10-05 2009-04-09 Univerzita Palackeho V Olomouci Dérivés de 6.(alkylbenzylamini)purine substitués s'utilisant comme antagonistes du récepteur de la cytokine et préparations contenant ces dérivés

Non-Patent Citations (68)

* Cited by examiner, † Cited by third party
Title
ABRAMS, M. J.; MURRER, B. A., SCIENCE, vol. 261, 1993, pages 725 - 730
ALI, M. S.; THURSTON, J. H.; WHITMIRE, K. H.; KHOKHAR, A. R., POLYHEDRON, vol. 21, 2002, pages 2659 - 2665
ALI, M.S.; THURSTON, J.H.; WHITMIRE, K.H.; KHOKHAR, A.R, POLYHEDRON, vol. 21, 2002, pages 2659 - 2665
ALVAREZ-VALDES, A.; PEREZ, J. M; LOPEZ-SOLERA, L.; LANNEGRAND, R.; CONTINENTE, J.M.; AMO-OCHOA, P.; CAMAZON, M.J; SOLANS, X; FONT-, J. MED. CHEM., vol. 45, 2002, pages 1835 - 1844
BEAGLEY, B.; CRUICKSHANK, D. W J.; MCAULIFFE, C. A.; PRITCHARD, R. G.; ZAKI, A. M.; BEDDOES, R. L.; CERNIK, R. J.; MILLS, O. S. J., MOL. STR., vol. 130, 1985, pages 97 - 102
BITHA, P.; CHILD, R. G.; HLAVKA, J.J.; LANG, S.A.; LIN, Y.-I.; HALTIWANGER, R. C.; PIERPONT, C.G., INORG. CHIM. ACTA, vol. 151, 1988, pages 89 - 93
BITHA, P.; CHILD, R.G.; HLAVKA, J.J.; LANG, S.A.; LIN, Y.- L.; HALTIWANGER, R.C.; PIERPONT, C.G., INORG. CHIM. ACTA, vol. 151, 1988, pages 89 - 93
BITHA, P.; MORTON, G. 0.; DUNNE, T. S.; SANTOS, E. F. D.; LIN, Y.; BOONE, S. R.; HALTIWANGER, R. C.; PIERPOINT, C. G., INORG. CHEM., vol. 29, 1990, pages 645 - 652
BITHA, P.; MORTON, G.O.; DUNNE, TS.; SANTOS, E.F.D.; LIN, Y.; BOONE, S.R.; HALTIWANGER, R. C.; PIERPONT, C.G., INORG. CHEM., vol. 29, 1990, pages 645 - 652
BRANDENBURG, K., CRYSTAL IMPACT GBR, BONN, GERMANY, 2006
BRUCK, M. A.; BAU, R.; NOJI, M.; INAGAKI, K.; KIDANI, Y., INORG. CHIM. ACTA, vol. 92, 1984, pages 279
BRUN, V.; LEGRAVEREND, M.; GRIERSON, D. S., TETRAHEDR. LETT., vol. 42, 2001, pages 8161 - 8164
BRUN, V.; LEGRAVEREND, M.; GRIERSON, D. S., TETRAHEDR. LETT., vol. 42, 2001, pages 8165 - 8167
BRUNNER, H.; MAITERTH, F.; TREITTINGER, B., CHEM. BER., vol. 127, 1994, pages 2141 - 2148
CARLAND, M.; TAN, K. J.; WHITE, J. M.; STEPHENSON, J.; MURRAY, V.; DENNY, W. A.; MCFADYEN, W. D. J., INORG. BIOCH., vol. 99, 2005, pages 1738 - 1743
CHEN, X; XIE, M.; LIU, M.; YE, Q.; YU, Y.; HOU, S.; GAO, W.; LIU,- Y., INORG. CHIM. ACTA, vol. 360, 2007, pages 2851 - 2856
DOUPLE, E. B.; RICHMOND, R. C.; O'HARA, J. A.; COUGHLIN, C. T., CANC. TREAT. REW., vol. 12, 1985, pages 111 - 124
DVORAK, LUKAS; POPA, IGOR; STARHA, PAVEL; TRAVNICEK, ZDENEK: "In Vitro Cytotoxic-Active Platinum(II) Complexes Derived from Carboplatin and Involving Purine Derivatives", EUROPEAN JOURNAL OF INORGANIC CHEMISTRY, 1 August 2010 (2010-08-01), pages 3441 - 3448, XP002616785 *
FERREIRA, A.D.Q.; BINO, A.; GIBBON, D., INORG. CHIM. ACTA, vol. 265, 1997, pages 155 - 161
FERREIRA, A.D.Q.; BINO, A.; GIBBON, D., LNORG. CHIM. ACTA, vol. 265, 1997, pages 155 - 161
FURUSE, K; FUKUOTA, M.; OHSHIMA, S., PROC. AM. SOC. CLIN. ONCOL., vol. 8, 1989, pages 238 - 243
GHEZZI, A. R.; ACETO, M.; CASSINO, C.; GABANO, E.; OSELLA. D. J., INORG. BIOCH., vol. 98, 2004, pages 73 - 78
HAMBLEY, T W., DALTON TRANS., vol. 120, 2001, pages 2711 - 2718
HANESSIAN, S.; WANG, J. CANC., J. CHEM., vol. 71, 1993, pages 886 - 895
HOLMES, R. E.; ROBINS, R. K., J. AM. CHEM. SOC., vol. 82, 1960, pages 3773 - 3779
INUYAMA, Y.; MIYAKE, H.; HORIUCHI, M.; HAYASAKI, K.; KOMIYAMA, S.; OHTA, K., JPN. J. CANCER CHEMOTHER., vol. 19, 1992, pages 863 - 869
KAMEYAMA, Y.; OKAZAKI, N.; NAKAGAWA, M.; KOSHIDA, H.; NAKAMURA, M.; GAMBA, M., TOXICOL. LETT., vol. 52, 1990, pages 15 - 24
KIDANI, Y.; INAGAKI, K., J. MED. CHEM., vol. 21, 1978, pages 1315 - 1318
KRAKER, A. J.; MOORE, C. W, CANCER RES., vol. 48, 1988, pages 9 - 13
LEE, E.J.; JUN, M.J.; SOHN, M.S., BULL. KOREAN CHEM. SOC., vol. 20, 1999, pages 1469 - 1474
LEE, S.S.; JUN, M.J.; JUNG, O.-S.; SOHN, Y.S., BULL. KOREAN CHEM. SOC., vol. 15, 1994, pages 84 - 86
LIU, W.; CHEN, X.; XIE, M.; LOU, L.; YE, Q.; YU, Y.; HOU, S., J. INORG. BIOCH., vol. 102, 2007, pages 1942 - 1946
LURA, A.; KATSUMATA, N.; KOUNO, T.; SHIMIZU, C.; ANDO, M.; FUJIWARA, Y., INT. J. GYNEC. OBST., vol. 105, 2009, pages 261 - 270
MALON, M.; TRAVNICEK, Z.; MAREK, R.; STRNAD, M., J. INORG. BIOCHEM., vol. 99, 2005, pages 2127 - 2138
MEELICH, K.; GALANSKI, M.; ARION, V.B.; KEPPLER, B.K., EUR. J. INORG. CHEM., 2006, pages 2476 - 2483
MING-JIN, X; YAO, Y.; WEI-PING, L.; SHU-QIAN, H.; XIZHU, C., ACTA CRYSTALLOGR., SECT.E: STRUCT. REP. ONLINE, vol. 63, 2007, pages 2728
MOK, D. W. S.; MOK, M. C., ANN. REV. PLANT PHYSIOL. PLANT MOL. BIOL., vol. 52, 2001, pages 89 - 118
MORAVEC, J.; KRYSTOF, V.; HANUS, J.; HAVLÍCEK, L.; MORAVCOVÁ, D.; FUKSOVÁ, K.; KUZMA, M.; LENOBEL, R.; OTYEPKA, M.; STRNAD, M., BIOORG. MED. CHEM. LETT, vol. 13, 2003, pages 2993 - 2996
NEIDLE, S; ISMAIL, I. M.; SADLER, P. J. J., INORG. BIOCH., vol. 13, 1980, pages 205 - 212
OXFORD DIFFRACTION, 2002
PECKHAM, M. J.; HORWICH, A.; BRADA, M.; DRURY, A.; HENDRY, W. F., CANC. TREAT. REW., vol. 12, 1985, pages 101 - 110
PRICE, J. H.; WILLIAMSON, A. N.; SCHRAMM, R. F.; WAYLAND, B. B., INORG. CHEM., vol. 11, 1972, pages 1280 - 1284
ROCHON, F. D.; MASSARWEH, G., INORG. CHIM. ACTA, vol. 359, 2006, pages 4095 - 4104
ROCHON, F.D.; GRUPA, L.M., INORG. CHIM. ACTA, vol. 306, 2000, pages 193 - 204
ROCHON, F.D.; MASSARWEH, G., INORG. CHIM. ACTA, vol. 359, 2006, pages 4095 - 4104
ROELEN, H.; VELDMAN, N.; SPEK, A. L.; VON FRIJTAG DRABBE KUNZEL, J.; MATHOT, R. A. A.; IJZERMAN, A. P., J. MED. CHEM., vol. 39, 1996, pages 1463 - 1471
ROSENBERG, B.; CAMP, V.; KRIGAS, T., NATURE, vol. 205, 1965, pages 689 - 699
See also references of EP2475673A1
SHAMSUDDIN, S.; KHOKHAR, A.R., J. COORD. CHEM., vol. 33, 1994, pages 83 - 91
SHELDRICK, G.M., SHELXL 97, PROGRAM FOR CRYSTAL STRUCTURE REFINEMENT, 1997
SHELDRICK, G.M., SHELXS 97, ACTA CRYST. A, vol. 46, 1990, pages 467
SKOOG, F.; HAMZI, H. Q.; SZWEYKOWSKA, A. M.; LEOPARD, N. J.; CARRAWAY, K. L.; FUJII, T.; HELGESON, J. P.; LOEPPKY, R. N., PHYTOCHEM., vol. 6, 1967, pages 1169 - 1192
STARHA, P.; TRAVNICEK, Z.; POPA, 1. J., INORG. BIOCHEM., vol. 104, 2010, pages 639 - 647
SZUCOVA, L. ET AL.: "Novel platinum(II) and palladium(II) complexes with cyclin-dependent kinase inhibitors: synthesis, characterization and antitumor activity", BIOORGANIC & MEDICINAL CHEMISTRY, 2006, pages 479 - 491, XP002616786 *
SZUCOVA, L.; TRAVNICEK, Z.; ZATLOUKAL, M.; POPA, I., BIOORG. MED. CHEM., vol. 14, 2006, pages 479 - 491
SZUCOVA; L.; TRAVNICEK, Z.; POPA, L.; MAREK, J., POLYHEDRON, vol. 27, 2008, pages 2710 - 2720
TASHIRO, T; KAWADA, Y.; SAKURAI, Y.; KIDANI, Y., BIOMED. PHARMACOTHER., vol. 43, 1989, pages 251 - 260
TOTANI, T.; AONO, K.; KOMURA, M.; ADACHI, Y., CHEM. LETT., vol. 3, 1986, pages 429 - 432
TRAVNICEK, Z.; MALON, M.; ZATLOUKAL, M.; DOLEZAL, K; STRNAD, M.; MAREK, J. J., INORG. BIOCHEM., vol. 94, 2003, pages 307 - 316
TRAVNICEK, Z.; POPA, L.; CAJAN, M.; HERCHEL, R.; MAREK, J., POLYHEDRON, vol. 26, 2007, pages 5271 - 5282
TRAVNICEK, Z.; STARHA, P.; POPA, L.; VRZAL, R.; DVORAK, Z., EUR. J. MED CHEM.
TU, C.; LIN, J.; SHAO, Y.; GUO, Z., INORG. CHEM., vol. 42, 2003, pages 5795 - 5797
TU, C.; WU, X; LIU, Q.; WANG, X; XU, Q.; GUO, Z., INORG. CHIM. ACTA, vol. 357, 2004, pages 95 - 102
VRZAL, R.; STARHA, P.; DVORAK, Z.; TRAVNICEK, J., INORG. BIOCHEM., vol. 104, 2010, pages 1130 - 1132
WEISS, R. B.; CHRISTIAN, M. C., DRUGS, vol. 46, 1993, pages 360 - 365
WILKINSON, A. R.; COX, P. J.; JONES, M.; HARRAP, K. R., BIOCHIMIE, vol. 60, 1978, pages 851
YONEI, M.; MURATA, H.; ITOH, M.; WATANABE, Y.; OCHI, K.; HONDA, M.; NAWATA, Y., ACTA CRYSTALLOGR., SECT.C: CRYST. STRUCT. COMMUN., vol. 46, 1990, pages 137 - 138
YOO, J.; SOHN, Y.S.; DO, Y., J. INORG. BIOCHEM., vol. 73, 1999, pages 187 - 193

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187191A1 (fr) * 2015-05-18 2016-11-24 Medoc Pharmaceutical Co., Ltd. Co-cristal pharmaceutique et son utilisation
US10751318B2 (en) 2015-05-18 2020-08-25 Syn-Nat Products Enterprise LLC Pharmaceutical co-crystal and use thereof
US10421770B2 (en) 2015-06-19 2019-09-24 Syn-Nat Products Enterprise LLC Pharmaceutical composition of carboplatin based co-crystals and use thereof
US10980768B2 (en) 2015-06-19 2021-04-20 Syn-Nat Products Enterprise LLC Composition containing carboplatin and use
US10428099B2 (en) 2015-06-25 2019-10-01 Syn-Nat Products Enterprise LLC Pharmaceutical co-crystal composition and use thereof

Also Published As

Publication number Publication date
CZ2009597A3 (cs) 2011-03-23
CZ302618B6 (cs) 2011-08-03
EP2475673A1 (fr) 2012-07-18

Similar Documents

Publication Publication Date Title
Castan et al. Platinum and palladium complexes of 3-methyl orotic acid: A route toward palladium complexes with good antitumor activity
US5107007A (en) Bis-platinum complexes as chemotherapeutic agents
Hadjiliadis et al. Platinum purine nucleosides. II. Interaction of K2PtX4 (X= Cl, Br) with inosine and guanosine
Summa et al. The impact of different chelating leaving groups on the substitution kinetics of mononuclear PtII (1, 2-trans-R, R-diaminocyclohexane)(X–Y) complexes
FI76351B (fi) Foerfarande foer framstaellning av 2,2-substituerade 1,3-alkandiaminplatina(ii)komplexer med antitumoeraktivitet.
EP2475673A1 (fr) Complexes cyclobutane-1,1-dicarboxylato de platine avec des dérivés de n6-benzyladénine, leur procédé de préparation et leur application en tant que médicaments dans un traitement antitumoral
JP3579423B2 (ja) ロバプラチナ三水和物
Rajković et al. Synthesis, spectroscopic and X-ray characterization of various pyrazine-bridged platinum (II) complexes: 1H NMR comparative study of their catalytic abilities in the hydrolysis of methionine-and histidine-containing dipeptides
Mahata et al. Influence of steric and electronic effect of carrier ligand on kinetics & mechanism of Pt (II) complexes with L-cysteine and its substituted derivatives: Their experimental and DFT-based theoretical study
Cubo et al. Influence of amine ligands on the aquation and cytotoxicity of trans-diamine platinum (II) anticancer complexes
CA2712408C (fr) Compose a base de complexe de platine et son utilisation
CN105481902A (zh) 以磷酸二氢根为轴向配体的铂(iv)抗癌化合物
WO2004099224A1 (fr) Complexes de platine (ii) de type carboplatine
US5770591A (en) Bis-platinum complexes as chemotherapeutic agents
EP2560980B1 (fr) Complexes anticancéreux d'osmium(ii)arène azo
CZ20271U1 (cs) Cyklobutan-1,1-di kar boxy látokomplexy platiny s deriváty N6- benzyladeninu
WO1989009598A1 (fr) Sulfoxydes d'amine de platine en tant qu'agents anti-tumoraux
Stitz Ligand substitution versus DNA-binding affinity: ǂb syntheses, structures, and in vitro anticancer activities of Pt (CH₃) ₂I₂ {2, 2'-bipy-n, n'-(CH₃) ₂}(n, n'= 4, 4'; 5, 5'; 6, 6')
Hussein et al. Design, Synthesis and In Silco studies of Metal Complexes with a Novel O, N, O-Donor Schiff Base Ligand
EP0613481B1 (fr) Complexes de platine triamino et leur procede de synthese
EP3795574A1 (fr) Synthèse et utilisation de complexes de 1,2-diaminodiamantane platine(ii)
Musumeci et al. Synthesis, DNA binding studies, and antiproliferative activity of novel Pt (II)-complexes with a L-alanyl-based ligand
Kojiyutoh et al. NEW TRIAMINE-TYPE PLATINUM (II) COMPLEXES OF PHENYL-SUBSTITUTED ETHYLENEDIAMINE: REACTIVITY WITH 5′-GMP
EP1427739A1 (fr) Polyamides de bisplatine cibles comme promedicaments : elimination selective du platine
Mustafa et al. Mixed Ligand Complexes of Platinum (IV) with some Amino acids and Dithiocarbamates or Dithiophosphates

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10776530

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010776530

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE